Scaling AAV manufacturing with confidence: upstream strategies to cut COGs and accelerate commercial readiness

The gene therapy landscape is expanding rapidly, but manufacturing costs remain the primary barrier to commercial and clinical accessibility. Therapy developers must rethink upstream strategy to reduce cost per dose without compromising quality. Early‑stage companies and emerging developers often struggle to scale beyond research formats, while CDMOs face pressure to expand capacity, increase flexibility, and accelerate tech transfer.

This webinar explores data‑driven, scalable, upstream solutions for transient AAV production, integrating insights from the iCELLis™ fixed‑bed platform, scalable Xcellerex™ X‑platform stirred‑tank bioreactors, and enhanced transient transfection workflows.

1 ^st April, 2026 11:00 AM EDT | 3:00 PM GMT | 4:00 PM CET

What you will learn:

Strategies to reduce COGs by adopting scalable upstream technologies and improving transient transfection efficiency
How to optimize V/A ratios and P/V strategies to enhance AAV production performance
Practical insights for biotech companies, therapeutic developers, and CDMOs to scale AAV manufacturing and prepare for commercial readiness

Who should attend:

Bioprocess Scientists
mAb Scientists
Upstream Process Development
Viral Vector Scientist
Gene Therapy Scientist
Process Development
Viral Vector Process Development
Gene Therapy Manufacturing
Viral Vector / Gene Therapy

Register Now

Would you like one of our specialists to reach out to you after the webinar? *

Yes, I would like to discuss upstream viral vector manufacturing strategies and solutions

No, thank you. I’m just here to learn

What type of organization do you work for? (Select the option that best describes your organization’s focus and stage) *

Academic or research institution

Preclinical biotech

Clinical biotech

Clinical-stage biopharma

Commercial-stage biopharma

Contract Research Organization (CRO)

Contract Development and Manufacturing Organization (CDMO)

Regulatory or government agency

Other

By clicking any of these options, you are agreeing to receive marketing emails, newsletters, and other promotional communications from Cytiva from time to time. You have a right to withdraw your consent at any time, by clicking here. We may still continue to send you service-related and other non-promotional communications. For more information relating to our privacy practices, we invite you to review our Privacy policy.

Phone call

Text messages

Kelly Cybulski
Kelly.Cybulski@Cytiva.com
Senior Scientist, R&D, Cytiva

Kelly Cybulski is a Senior Scientist in R&D at Cytiva. She holds a Master of Science degree in Cell and Molecular Biology from the University of Rhode Island and brings 19 years of experience spanning GMP manufacturing, process development, and research and development. Over the past six years at Cytiva, Kelly has specialized in viral vector process and product development, contributing deep technical expertise to advancing scalable and robust solutions.

Emmanuelle Cameau
emmanuelle.cameau@cytiva.com
Scientific Director – Viral Vectors, Cytiva

Emmanuelle is driven to solve customer challenges such as how to reduce manufacturing burdens through process improvement and innovative solutions. She has a proven track record and 19+ years of experience in process development and the manufacturing of biologics and advanced therapies, especially viral vectors and stem cells, and currently works for Cytiva as Scientific Director, Viral Vectors.